BFS
NBIX icon

Bare Financial Services’s Neurocrine Biosciences NBIX Stock Holding History

Bare Financial Services’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.57K Buy
39
+2
+5% +$297 ﹤0.01% 754
2026
Q1 		$4.87K Buy
37
+1
+3% +$133 ﹤0.01% 656
2025
Q4 		$5.11K Buy
36
+1
+3% +$145 ﹤0.01% 532
2025
Q3 		$4.91K Buy
35
+5
+17% +$677 ﹤0.01% 542
2025
Q2 		$3.77K Buy
+30
New +$3.44K ﹤0.01% 609

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Bare Financial Services's NBIX Position: Q2 2026 in Review

Bare Financial Services increased its Neurocrine Biosciences (NBIX) stake by 5.4% in Q2 2026, buying an estimated $297 and bringing the position to 39 shares worth $6.57K. The position accounts for ﹤0.01% of the portfolio, ranked #754.

Bare Financial Services first reported a position in NBIX in Q2 2025 and has held it in 5 quarters since. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Bare Financial Services held 39 shares of Neurocrine Biosciences worth $6.57K as of Q2 2026.
  • Bare Financial Services bought 2 Neurocrine Biosciences shares in Q2 2026, an estimated $297.
  • Neurocrine Biosciences made up ﹤0.01% of Bare Financial Services's portfolio in Q2 2026, its #754 holding.
  • Bare Financial Services first reported a position in Neurocrine Biosciences in Q2 2025 and has held it in 5 quarters since.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Bare Financial Services's 13F filing for Q2 2026, filed 27 Jul 2026.